Loading...
•
Jun 30, 2023
Neurocrine Biosciences Q2 2023 Earnings Report
Neurocrine Biosciences reported Q2 2023 financial results and raised 2023 INGREZZA sales guidance.
Key Takeaways
Neurocrine Biosciences announced positive financial results for the second quarter ended June 30, 2023. INGREZZA's performance enabled the company to raise its net sales guidance for 2023, with a strong operational setup for the second half of the year.
INGREZZA second quarter net product sales were $440 million, a 26% increase year-over-year.
A record number of new patients received INGREZZA therapy during the second quarter of 2023.
Second quarter GAAP net income was $96 million, or $0.95 per share, compared to a net loss of $17 million, or $0.18 per share, in the second quarter of 2022.
Second quarter non-GAAP net income was $126 million, or $1.25 per share, compared to $82 million, or $0.84 per share, in the second quarter of 2022.
Neurocrine Biosciences
Neurocrine Biosciences
Neurocrine Biosciences Revenue by Segment
Revenue by Segment
INGREZZA Revenue
CapyFin.com Forward Guidance
Neurocrine Biosciences updated its 2023 INGREZZA sales guidance and reaffirmed its operating expense guidance.
Positive Outlook
- INGREZZA Net Product Sales: $1,770 - $1,820 million
- GAAP R&D Expense: $550 - $580 million
- Non-GAAP R&D Expense: $495 - $525 million
- GAAP and Non-GAAP IPR&D: $144 million
- GAAP SG&A Expense: $850 - $870 million
Challenges Ahead
- Non-GAAP SG&A Expense: $730 - $750 million
- GAAP R&D guidance includes amounts for milestones that are probable of achievement or have been achieved.
- Non-GAAP guidance adjusted to exclude estimated non-cash stock-based compensation expense of $65 million in R&D and $135 million in SG&A.
- IPR&D guidance reflects acquired in-process research and development once significant collaboration and licensing arrangements have been completed.
- IPR&D guidance includes $143.9 million associated with the new strategic collaboration with Voyager.